The Latest News

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Shanghai-Based Biotech, Backed by Preeminent VCs, Seeks Chief Medical Officer

Occam Global is a strategic executive search firm with substantial experience serving entrepreneurial companies in the Healthcare and Technology sectors.

USCACA Board of Director Member in the News

Jan. 21st, 2015, Paris

2014 Chinese Clinical Oncology Advances Awards Announced

2014 Chinese Clinical Oncology Advances Awards Announced
From China Medical Tribune

USCACA sponsor - Chipscreen has its drug approved in China

Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
SHENZHEN, China, Jan. 09, 2015 /PRNewswire/ -- Chipscreen Biosciences today announced regulatory approval of Chidamide (Epidaza®), the world first orally administrated and subtype-selective histone deacetylase (HDAC) inhibitor for relapsed or refractory peripheral T-cell lymphoma (PTCL) patients, in China on Dec. 23, 2014 by the Chinese Food and Drug Administration (CFDA).

International Collaboration Drives Discovery of Link Between Breast/Ovarian Cancer Gene and Stomach Cancer

BETHESDA, Md., Jan. 16, 2015 /PRNewswire-USNewswire/ -- A team of scientists from the United States and China has discovered new genetic insights that could change the way oncologists treat gastric cancer, the fourth most common cancer and the second leading cause of cancer death in the world. The investigators, who tested hundreds of gastric cancer tissue samples using advanced whole-genome sequencing technology, published their discovery online on January 12 in the Proceedings of National Academy of Sciences.

USCACA president was interviewed by CCTV-america on cancer issues

USCACA president was interviewed by CCTV-america on cancer issues

Check the link here:
http://youtu.be/z5CybZlufQs

CMT and CSCO announce the 2013 Chinese Clinical Oncology Advances Awards

The 2013 Chinese Clinical Oncology Advancement Award was recently announced. A total of 14 research programs received the award organized by China Medical Tribune (CMT) and the Chinese Society of Clinical Oncology (CSCO). These projects covered a broad spectrum of clinical oncology specialty fields and were published in prestigious journals including Lancet Oncology and Journal of Clinical Oncology. USCACA clinical oncology research experts participated the award review and selection as special panel reviewers.

USCACA partner --CJC Wins the Title of 2013’ the Highest International Impact Academic Journal of China

"As the partner of the Chinese Journal of Cancer (CJC) for the past 3 years, USCACA is proud to announce that our society journal CJC wins the Title of 2013’s Highest International Impact Academic Journal of China. Below is a news release from Sun Yat-sen University where CJC is headquartered. Members of USCACA have organized a number of special issues on important topics including Cancer Drug Discovery, Systems Biology of Cancer, Cancer Autophagy, Mouse Model of Cancer, Signaling pathways of Cancer."

Four outstanding young Chinese scientists received the 2013 Scholar Award from USCACA and NFCR

To facilitate and strengthen collaborations among cancer researchers and physicians in the United States and China, the US Chinese Anti-Cancer Association (USCACA) and the National Foundation for Cancer Research (NFCR) have established the Scholar Excellence Award for the USCACA-NFCR Scholar Exchange and Fellowship Program in Basic, Translational, and Clinical Studies.

USCACA partner -- The Chinese Journal of Cancer is supported by the International Impact-promoting Program for Chinese Sci-Tech Journals

Recently, the International Impact-promoting Program for Chinese Sci-Tech Journals has released the journal selection results. The Chinese Journal of Cancer (CJC), an English journal sponsored by Sun Yat-sen University Cancer Center, gained type B grant support from this program, with an annual national funding of 1,000,000 RMB for 3 consecutive years.

Pages